230 related articles for article (PubMed ID: 9317016)
1. Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.
Blackstock R; Murphy JW
Infect Immun; 1997 Oct; 65(10):4114-21. PubMed ID: 9317016
[TBL] [Abstract][Full Text] [Related]
2. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
3. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.
Chang YC; Cherniak R; Kozel TR; Granger DL; Morris LC; Weinhold LC; Kwon-Chung KJ
Infect Immun; 1997 May; 65(5):1584-92. PubMed ID: 9125534
[TBL] [Abstract][Full Text] [Related]
4. Role of the capsule in phagocytosis of Cryptococcus neoformans.
Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
Rev Infect Dis; 1988; 10 Suppl 2():S436-9. PubMed ID: 3055212
[TBL] [Abstract][Full Text] [Related]
5. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
6. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy.
da Silva TA; Hauser PJ; Bandey I; Laskowski T; Wang Q; Najjar AM; Kumaresan PR
Cytotherapy; 2021 Feb; 23(2):119-130. PubMed ID: 33303326
[TBL] [Abstract][Full Text] [Related]
7. Regulated Release of Cryptococcal Polysaccharide Drives Virulence and Suppresses Immune Cell Infiltration into the Central Nervous System.
Denham ST; Verma S; Reynolds RC; Worne CL; Daugherty JM; Lane TE; Brown JCS
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203547
[No Abstract] [Full Text] [Related]
8. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.
Chang ZL; Netski D; Thorkildson P; Kozel TR
Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967
[TBL] [Abstract][Full Text] [Related]
9. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
[TBL] [Abstract][Full Text] [Related]
10. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
Young BJ; Kozel TR
Infect Immun; 1993 Jul; 61(7):2966-72. PubMed ID: 8514401
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
Zaragoza O; Casadevall A
Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
[TBL] [Abstract][Full Text] [Related]
12. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
13. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans.
Cross CE; Collins HL; Bancroft GJ
Immunology; 1997 Jun; 91(2):289-96. PubMed ID: 9227330
[TBL] [Abstract][Full Text] [Related]
14. The Overlooked Glycan Components of the Cryptococcus Capsule.
Fonseca FL; Reis FCG; Sena BAG; Jozefowicz LJ; Kmetzsch L; Rodrigues ML
Curr Top Microbiol Immunol; 2019; 422():31-43. PubMed ID: 30203395
[TBL] [Abstract][Full Text] [Related]
15. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
Pirofski LA
Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
[TBL] [Abstract][Full Text] [Related]
16. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
[TBL] [Abstract][Full Text] [Related]
17. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.
Wilson MA; Kozel TR
Infect Immun; 1992 Mar; 60(3):754-61. PubMed ID: 1541548
[TBL] [Abstract][Full Text] [Related]
18. Receptor-mediated recognition of Cryptococcus neoformans.
Levitz SM
Nihon Ishinkin Gakkai Zasshi; 2002; 43(3):133-6. PubMed ID: 12145626
[TBL] [Abstract][Full Text] [Related]
19.
Colombo AC; Rella A; Normile T; Joffe LS; Tavares PM; de S Araújo GR; Frases S; Orner EP; Farnoud AM; Fries BC; Sheridan B; Nimrichter L; Rodrigues ML; Del Poeta M
mBio; 2019 Apr; 10(2):. PubMed ID: 30940711
[No Abstract] [Full Text] [Related]
20. Isolation and purification of antigenic components of Cryptococcus.
Wozniak KL; Levitz SM
Methods Mol Biol; 2009; 470():71-83. PubMed ID: 19089377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
